Urinary metabolomics predicts early rituximab response in steroid-nonresponsive pediatric patients with primary immune thrombocytopenia
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06453-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Yuncui Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No.…. Hauptthemen laut MEDLINE: Metabolomics, Purpura, Thrombocytopenic, Idiopathic, Rituximab, Steroids. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Children's Medication Program of Beijing Children's Hospital, Children's Medication Program of Beijing Children’s Hospital.
Abstract (Originalsprache)
Rituximab (RTX) is an effective therapy for pediatric steroid-nonresponsive immune thrombocytopenia (ITP), yet persistent challenges remain in predicting early therapeutic responses. To address this, we conducted a prospective cohort study analyzing serial urine samples from 37 steroid-nonresponsive ITP patients (17 RTX responders (RTX-R), 20 non-responders (RTX-NR)) and 38 age- and sex-matched controls using untargeted LC-MS metabolomics. We identified 16 pretreatment and 2 posttreatment metabolites distinguishing RTX-R from RTX-NR. Pretreatment metabolic pathway analysis in RTX-R revealed significant enrichment in folate-mediated one-carbon pool, ether lipid metabolism, porphyrin metabolism, and amino acid metabolism (cysteine/methionine, arginine/proline), and purine pathways. Longitudinal clustering analysis demonstrated RTX-induced metabolic changes in purine metabolism, pantothenate and CoA biosynthesis, beta oxidation of fatty acids, and valine, leucine and isoleucine biosynthesis. A machine learning-derived predictive model incorporating seven metabolites (N6-methyl-2’-deoxyadenosine, dopamine 4-sulfate, DL-homocystine, folinic acid, S-adenosylmethioninamine, lysoPA (P-16:0e/0:0), and coproporphyrinogen III) demonstrated robust stratification of patients eligible for RTX before treatment (AUC 0.85 ± 0.13). Complementing this, a two-metabolite (N6-methyl-2’-deoxyadenosine and dehydroepiandrosterone) monitoring model was developed to track treatment responsiveness dynamically (AUC 0.83 ± 0.16). This study elucidates metabolic mechanisms underlying RTX responsiveness and delivers clinically actionable tools to enhance personalized management of pediatric ITP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Center, Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No.56 Nanlishi Road, Beijing, 100045, China.
- Department of Clinical Laboratory Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Department of Hematology, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education,…
- Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Clinical Research Center, Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No.56 Nanlishi Road, Beijing, 100045, China. guopeng@bch.com.cn.
- Laboratory of Tumor Immunology, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No.56 Nanlishi Road, Beijing, 100045, China. guijinga…
Förderung
- National Natural Science Foundation of China
- Children's Medication Program of Beijing Children's Hospital
- Children's Medication Program of Beijing Children’s Hospital
Zitieren
APA
Yu, Y., Chen, Z., Wei, J., Xie, X., Ouyang, J., Lin, Z., Ma, J., Guo, P., Wu, R., & Gui, J. (2025). Urinary metabolomics predicts early rituximab response in steroid-nonresponsive pediatric patients with primary immune thrombocytopenia. Annals of Hematology. https://doi.org/10.1007/s00277-025-06453-4
Vancouver
Yu Y, Chen Z, Wei J, Xie X, Ouyang J, Lin Z, et al. Urinary metabolomics predicts early rituximab response in steroid-nonresponsive pediatric patients with primary immune thrombocytopenia. Annals of Hematology. 2025. doi:10.1007/s00277-025-06453-4
BibTeX
@article{Yu2025,
author = {Yu, Yuncui and Chen, Zhenping and Wei, Jing and Xie, Xingjuan and Ouyang, Juntao and Lin, Zheyan and Ma, Jingyao and Guo, Peng and Wu, Runhui and Gui, Jingang},
title = {Urinary metabolomics predicts early rituximab response in steroid-nonresponsive pediatric patients with primary immune thrombocytopenia},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06453-4}
}
EUVIMED